xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT06021756</url>
    </required_header>
    <id_info>
      <org_study_id>1903472458_ MOD00004091</org_study_id>
      <nct_id>NCT06021756</nct_id>
    </id_info>
    <brief_title>Phase I Open-label Study of Low-dose Ketamine Infusion Treatment in Levodopa-Induced Dyskinesia in Parkinson's Disease</brief_title>
    <official_title>A Single-center Phase I Open-label Study of the Tolerability and Efficacy of Low-dose Ketamine Infusion for Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>University of Arizona</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
      <collaborator>
        <agency>Scott Richards</agency>
        <agency_class>Other</agency_class>
      </collaborator>
    </sponsors>
    <source>University of Arizona</source>
    <oversight_info>
      <has_dmc>Yes</has_dmc>
      <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
      <is_us_export>Yes</is_us_export>
    </oversight_info>
    <brief_summary>
      <textblock>
        The primary objective is to determine the tolerability and efficacy of a low-dose ketamine&#xD;
        infusion for the treatment of Levodopa-Induced dyskinesias (LID), both acutely and during&#xD;
        post-infusion evaluation (week 2-6), as measured by a change in patient diaries of dyskinesia&#xD;
        and the UDysRS. Secondary objectives include observing the effects of ketamine on various&#xD;
        symptoms of Parkinson's disease and Levodopa side effects. This includes the duration of&#xD;
        &quot;off,&quot; &quot;on without dyskinesia,&quot; and &quot;troublesome dyskinesia&quot; time during waking hours,&#xD;
        effects on chronic and acute pain, quality of life, and other general PD symptoms as noted in&#xD;
        the Unified Parkinson's Disease Rating Scale.&#xD;
  &#xD;
        There is no highly effective treatment for levodopa-induced dyskinesia. This research study&#xD;
        will use intermittent infusions of ketamine, on 10 volunteer subjects, which could provide&#xD;
        significant improvement in dyskinesia utilizing a novel mechanism of action compared to&#xD;
        current treatment strategies. Positive results in this study could lead to new novel&#xD;
        treatments for dyskinesia and further development for other PD symptoms such as depression&#xD;
        and pain.&#xD;
      </textblock>
    </brief_summary>
    <overall_status>Active, not recruiting</overall_status>
    <start_date type="Actual">July 28, 2019</start_date>
    <completion_date type="Anticipated">August 25, 2023</completion_date>
    <primary_completion_date type="Actual">August 25, 2022</primary_completion_date>
    <phase>Phase 1</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>N/A</allocation>
      <intervention_model>Single Group Assignment</intervention_model>
      <primary_purpose>Treatment</primary_purpose>
      <masking>None (Open Label)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>Change in the Unified Dyskinesia Rating Scale (UDysRS) total score</measure>
      <time_frame>2 and 12 weeks</time_frame>
      <description>Change in the Unified Dyskinesia Rating Scale (UDysRS) total score from Baseline to Week 2 and 12</description>
    </primary_outcome>
    <number_of_arms>1</number_of_arms>
    <enrollment type="Actual">9</enrollment>
    <condition>Levodopa-Induced Dyskinesia</condition>
    <condition>Parkinson's Disease</condition>
    <arm_group>
      <arm_group_label>Intervention: Ketamine</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Ketamine will be administered as intravenous infusions with infusion rates ranging from 0.05 mg/kg/hr to 0.30 mg/kg/hr.</description>
    </arm_group>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>Intervention: Ketamine</intervention_name>
      <description>Ketamine will be administered as intravenous infusions with infusion rates ranging from 0.05 mg/kg/hr to 0.30 mg/kg/hr.</description>
      <arm_group_label>Intervention: Ketamine</arm_group_label>
      <other_name>Intervention: Ketamine i.v.</other_name>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            -  Patients diagnosed with Parkinson's Disease as defined by the UK Parkinson's Disease&#xD;
               Society Brain Bank Criteria&#xD;
  &#xD;
            -  Be male or female between ages 30-85&#xD;
  &#xD;
            -  Be on at least two years of treatment of levodopa of at least 400 mg or 4mg/kg daily&#xD;
  &#xD;
            -  Have levodopa induced dyskinesia for at least 2 hours per day&#xD;
  &#xD;
            -  Have been on stable doses of all anti-Parkinson's medications for 30 days and be&#xD;
               willing to remain on the same doses throughout the course of the study&#xD;
  &#xD;
            -  The subject/caregiver must demonstrate ability to complete an accurate home diary&#xD;
               based on training and evaluation (visit 2)&#xD;
  &#xD;
            -  Female subjects not of childbearing potential&#xD;
  &#xD;
                 -  infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, or&#xD;
                    tubal ligation), congenital anomaly such as Mullerian agenesis; or&#xD;
  &#xD;
                 -  post-menopausal - defined as either&#xD;
  &#xD;
                      -  A woman at least 40 years of age with an intact uterus, not on hormone&#xD;
                         therapy, who has had at least 1 year of spontaneous amenorrhea with a&#xD;
                         follicle-stimulating hormone level &gt;40 mIU/mL&#xD;
  &#xD;
                      -  A woman 55 or older not on hormone therapy, who has had at least 6 months of&#xD;
                         spontaneous amenorrhea&#xD;
  &#xD;
                      -  A woman at least 55 years of age with a diagnosis of menopause prior to&#xD;
                         start of hormone replacement therapy.&#xD;
  &#xD;
            -  Male subjects, regardless of their fertility status, with nonpregnant women of&#xD;
               childbearing potential (WOCBP) partners must agree to either remain abstinent (if this&#xD;
               is their preferred and usual lifestyle) or use a highly effective (less than 1%&#xD;
               failure rate) method of contraception (such as combination oral contraceptives,&#xD;
               implanted contraceptives, or intrauterine devices) or effective method of&#xD;
               contraception (such as diaphragms with spermicide or cervical sponges) for the&#xD;
               duration of the study and until their plasma concentrations are below the level that&#xD;
               could result in a relevant potential exposure to a possible fetus, predicted to be 90&#xD;
               days following the last dose of study drug.&#xD;
  &#xD;
                 -  Men and their partners may choose to use a double-barrier method of&#xD;
                    contraception. (Barrier protection methods without concomitant use of a&#xD;
                    spermicide are not an effective or acceptable method of contraception. Thus, each&#xD;
                    barrier method must include use of a spermicide. It should be noted, however,&#xD;
                    that the use of male and female condoms as a double barrier method is not&#xD;
                    considered acceptable due to the high failure rate when these barriers' methods&#xD;
                    are combined). Men with pregnant partners should use condoms during intercourse&#xD;
                    for the duration of the study and until the end of estimated relevant potential&#xD;
                    exposure in WOCBP (90 days).&#xD;
  &#xD;
                 -  Men should refrain from sperm donation for the duration of the study and until&#xD;
                    their plasma concentrations are below the level that could result in a relevant&#xD;
                    potential exposure to a possible fetus, predicted to be 90 days following the&#xD;
                    last dose of study drug.&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  Diagnosis of an atypical or secondary parkinsonian syndrome&#xD;
  &#xD;
            -  Lack of documented response to levodopa&#xD;
  &#xD;
            -  Prior exposure to ketamine within the last one year&#xD;
  &#xD;
            -  Significant history of premorbid psychiatric illness other than depression&#xD;
  &#xD;
            -  Currently taking psychotropic medications with significant dopamine receptor blocking&#xD;
               effects such as first-generation antipsychotic agents (clozapine, quetiapine,&#xD;
               pimavanserin are allowed as concomitant medications - see section 5.4)&#xD;
  &#xD;
            -  Have used antipsychotic medications, with the exception of clozapine, quetiapine,&#xD;
               pimavanserin in the 6 months prior to screening (Visit 1) and at any time during the&#xD;
               course of the study&#xD;
  &#xD;
            -  Cognitive impairment as demonstrated as a score of 20 or below on the Montreal&#xD;
               Cognitive Assessment (MoCA)&#xD;
  &#xD;
            -  Has a history of drug or alcohol dependence or abuse&#xD;
  &#xD;
            -  History of visual or auditory hallucinations (visual hallucinations will be acceptable&#xD;
               if scored 2 or less on UPDRS II)&#xD;
  &#xD;
            -  Serious or unstable medical condition that would increase risk in view of the&#xD;
               principal investigator.&#xD;
  &#xD;
            -  The subject is female, and is pregnant or lactating at the time of pregnancy or has&#xD;
               positive pregnancy test result at screening.&#xD;
  &#xD;
            -  Baseline BP &gt;160/95 on average of three readings at the screening visit&#xD;
  &#xD;
            -  History of arrhythmia, unstable angina, or significant cardiac dysfunction&#xD;
  &#xD;
            -  Have significant central nervous system disease, other than PD, that may affect&#xD;
               cognition or the ability to complete the study, including but not limited to other&#xD;
               dementias (e.g., Alzheimer's disease [AD]).&#xD;
  &#xD;
            -  Have a history in the last 6 months of transient ischemic attacks or stroke.&#xD;
  &#xD;
            -  Have a history of intracerebral hemorrhage due to hypertension.&#xD;
  &#xD;
            -  Have a history of hypertensive encephalopathy.&#xD;
  &#xD;
            -  If the Investigator believes that the subject would not be a good fit for the study&#xD;
               for any reason.&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>30 Years</minimum_age>
      <maximum_age>85 Years</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Scott J Sherman</last_name>
      <role>Principal Investigator</role>
      <affiliation>University of Arizona Health Sciences Center - Dep. of Neurology</affiliation>
    </overall_official>
    <location>
      <facility>
        <name>Scott J Sherman</name>
        <address>
          <city>Tucson</city>
          <state>Arizona</state>
          <zip>85724</zip>
          <country>United States</country>
        </address>
      </facility>
    </location>
    <location_countries>
      <country>United States</country>
    </location_countries>
    <verification_date>August 2023</verification_date>
    <study_first_submitted>August 27, 2023</study_first_submitted>
    <study_first_submitted_qc>August 27, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">September 1, 2023</study_first_posted>
    <last_update_submitted>August 27, 2023</last_update_submitted>
    <last_update_submitted_qc>August 27, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">September 1, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Principal Investigator</responsible_party_type>
      <investigator_affiliation>University of Arizona</investigator_affiliation>
      <investigator_full_name>Scott Sherman</investigator_full_name>
      <investigator_title>Scott J. Sherman MD, PhD,</investigator_title>
    </responsible_party>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Parkinson Disease</mesh_term>
      <mesh_term>Dyskinesias</mesh_term>
    </condition_browse>
    <intervention_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Ketamine</mesh_term>
    </intervention_browse>
    <patient_data>
      <sharing_ipd>No</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT06021756
  org study id: 1903472458_ MOD00004091
  nct id: NCT06021756
  lead sponsor: 
  collaborator: 
  has dmc: Yes
  is fda regulated drug: Yes
  is fda regulated device: No
  is us export: Yes
  The primary objective is to determine the tolerability and efficacy of a low-dose ketamine
        infusion for the treatment of Levodopa-Induced dyskinesias (LID), both acutely and during
        post-infusion evaluation (week 2-6), as measured by a change in patient diaries of dyskinesia
        and the UDysRS. Secondary objectives include observing the effects of ketamine on various
        symptoms of Parkinson's disease and Levodopa side effects. This includes the duration of
        "off," "on without dyskinesia," and "troublesome dyskinesia" time during waking hours,
        effects on chronic and acute pain, quality of life, and other general PD symptoms as noted in
        the Unified Parkinson's Disease Rating Scale.
  
        There is no highly effective treatment for levodopa-induced dyskinesia. This research study
        will use intermittent infusions of ketamine, on 10 volunteer subjects, which could provide
        significant improvement in dyskinesia utilizing a novel mechanism of action compared to
        current treatment strategies. Positive results in this study could lead to new novel
        treatments for dyskinesia and further development for other PD symptoms such as depression
        and pain.
  allocation: N/A
  intervention model: Single Group Assignment
  primary purpose: Treatment
  masking: None (Open Label)
  measure: Change in the Unified Dyskinesia Rating Scale (UDysRS) total score
  time frame: 2 and 12 weeks
  description: Change in the Unified Dyskinesia Rating Scale (UDysRS) total score from Baseline to Week 2 and 12
  arm group label: Intervention: Ketamine
  arm group type: Experimental
  description: Ketamine will be administered as intravenous infusions with infusion rates ranging from 0.05 mg/kg/hr to 0.30 mg/kg/hr.
  intervention type: Drug
  intervention name: Intervention: Ketamine
  description: Ketamine will be administered as intravenous infusions with infusion rates ranging from 0.05 mg/kg/hr to 0.30 mg/kg/hr.
  arm group label: Intervention: Ketamine
  other name: Intervention: Ketamine i.v.
  criteria: 
  gender: All
  minimum age: 30 Years
  maximum age: 85 Years
  healthy volunteers: No
  last name: Scott J Sherman
  role: Principal Investigator
  affiliation: University of Arizona Health Sciences Center - Dep. of Neurology
  facility: 
  country: United States
  responsible party type: Principal Investigator
  investigator affiliation: University of Arizona
  investigator full name: Scott Sherman
  investigator title: Scott J. Sherman MD, PhD,
  mesh term: Parkinson Disease
  mesh term: Dyskinesias
  mesh term: Ketamine
  sharing ipd: No